Omgenis
Develops a single-use periodontal bone reconstruction system for dental and periodontal care
Highlights
- Young companyFounded 2026
- New on EvolcAdded 2026-10-31
About Omgenis
Omgenis develops a site-specific, single-use system containing resorbable magnesium–PLGA composite microparticles for periodontal bone reconstruction. The system is designed to provide magnesium-associated osteopromotive and immunomodulatory effects without antibiotics.
Omgenis Oy is based in Turku, Finland, and was founded in 2026. Its team includes co-founders with life-sciences, biodegradable materials and dental research experience.
Product: A single-use, site-specific system containing resorbable magnesium–PLGA composite microparticles for periodontal bone reconstruction.
Jobs at Omgenis
Leadership
- Charles S. Sfeir · CSO & Co-founderSource: company website
- Tomi Numminen · CEO & Co-founderSource: company website
- Timo Lehtonen · CTO & Co-founderSource: company website
More biotech & pharma companies
Origin by Ocean
Bio-based fucoidan and alginate ingredients from invasive Sargassum for cosmetics, food and technical product formulatorsNew on EvolcOriola
Pharmaceutical and health product distribution, wholesale and advisory services for suppliers and pharmacies in the NordicsNew on EvolcPharmamile
Marketing, sales and consulting for veterinary medicines and feed supplements, serving animal health industry players in FinlandYoung companyNew on EvolcPolku Therapeutics
Develops small-molecule therapies for neurodegenerative diseases by targeting tau aggregation and neuroinflammationYoung companyNew on EvolcPrecisionPhage
Phage genome bioinformatics software, lab services and a phage library for AMR and phage therapy researchYoung companyNew on EvolcPrimoceler
Hermetic glass packaging and laser bonding for active implantable device electronics, from prototype to series productionNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- AWS
- Cloudflare
- Webflow